阿帕提尼布加化学疗法治疗非转移性骨髓瘤:一项回顾性队列研究
Jiaqiang Wang1, Fan Zhang1, Shuping Dong1
1Department of Orthopedics, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan, China.
Frontiers in oncology
|November 29, 2023
概括
阿帕提尼布加上多克索鲁比辛和西斯普拉丁 (AP) 显示出作为骨髓瘤的新辅助疗法的潜力,改善了生存趋势. 然而,这种组合疗法也增加了某些不良事件,需要进一步调查.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 有效的辅助疗法对于改善骨髓瘤结局至关重要.
- 以前的研究表明,阿帕蒂尼布与基于多克索鲁比的化疗相结合可能会提高新辅助疗法的疗效.
- 这项研究评估了阿帕蒂尼布加多克索鲁比辛和西斯普拉丁 (AP) 作为骨髓瘤的新辅助治疗方法.
研究的目的:
- 评估阿帕蒂尼布加AP作为骨髓瘤的新辅助疗法的有效性.
- 与标准化疗相比,评估阿帕蒂尼布加AP的安全性.
- 确定对无病生存率和不良事件的影响.
主要方法:
- 来自骨髓瘤患者的临床数据的回顾性分析 (2016年8月 - 2022年4月).
- 患者被分为两个组:阿帕丁尼布+AP和甲状腺素,多克索鲁比辛和西斯普拉丁 (MAP).
- 1年和2年无病生存率和不良事件发生率的比较.
主要成果:
- 与MAP组相比,阿帕丁尼布+AP组的1年和2年无病生存率较高,尽管在统计学上并不显著.
- 在阿帕蒂尼布+AP组中观察到明显更高的口腔粘膜炎,四肢,手脚综合征,蛋白尿,高血压和甲状腺功能低下症.
- 两组之间手术后并发症或与药物相关的死亡没有显著差异.
结论:
- 阿帕提尼布+AP显示为治疗骨髓瘤的新辅助疗法具有前途.
- 通过潜在的随机对照试验和长期随访进行进一步验证是有必要的.
- 特定不良事件的发病率增加需要仔细监测和管理.
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K